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ABSTRACT
Objective Antibodies to cell surface central nervous
system proteins help to diagnose conditions which often
respond to immunotherapies. The assessment of
antibody assays needs to reflect their clinical utility. We
report the results of a multicentre study of aquaporin
(AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis
optica spectrum disorders (NMOSD).
Methods Coded samples from patients with
neuromyelitis optica (NMO) or NMOSD (101) and
controls (92) were tested at 15 European diagnostic
centres using 21 assays including live (n=3) or fixed
cell-based assays (n=10), flow cytometry (n=4),
immunohistochemistry (n=3) and ELISA (n=1).
Results Results of tests on 92 controls identified
12assays as highly specific (0–1 false-positive results). 32
samples from 50 (64%) NMO sera and 34 from 51 (67%)
NMOSD sera were positive on at least two of the 12
highly specific assays, leaving 35 patients with
seronegative NMO/spectrum disorder (SD). On the basis of
a combination of clinical phenotype and the highly specific
assays, 66 AQP4-Ab seropositive samples were used to
establish the sensitivities (51.5–100%) of all 21 assays.
The specificities (85.8–100%) were based on 92 control
samples and 35 seronegative NMO/SD patient samples.
Conclusions The cell-based assays were most sensitive
and specific overall, but immunohistochemistry or flow
cytometry could be equally accurate in specialist centres.
Since patients with AQP4-Ab negative NMO/SD require
different management, the use of both appropriate
control samples and defined seronegative NMOSD
samples is essential to evaluate these assays in a
clinically meaningful way. The process described here can
be applied to the evaluation of other antibody assays in
the newly evolving field of autoimmune neurology.
INTRODUCTION
Assays to detect pathogenic antibodies have gained
importance in the past 10 years with the discovery
of new diseases that appear to be mediated by
antibodies to proteins such as aquaporin (AQP) 4
(identified in 2005),1 2 n-methyl-d-aspartate
(NMDA) receptor (2007),3 4 glycine receptor
(2008),5 a-amino-3-hydroxy-5-methyl-isoxazole-
propionic acid receptor (2009),6 gamma-aminobu-
tyric acid (GABA)B receptor (2009),
7 leucine-rich,
glioma inactivated 1 (LGI1) (2010),8 9 contactin-
associated protein like 2 (CASPR2) (2010)9 10 and
GABAA receptor (2014)
11 12 among others (for
reviews, see).13–15 The accurate and rapid detection
of these antibodies in patient serum or cerebro-
spinal fluid (CSF) can lead to immunotherapies that
reduce patient morbidity and mortality.
Neuromyelitis optica (NMO) was the first
antibody-mediated central nervous system (CNS)
disease with a clearly defined target, AQP4, identi-
fied in a variable proportion of patients. NMO can
be defined clinically; the patients present with epi-
sodes of optic neuritis (ON) and transverse myelitis
(TM) and brain lesions distinct from those found in
multiple sclerosis (MS),16 but it is unusual for the
full spectrum to be evident at the first episode. In
the past, many patients with NMO have been mis-
diagnosed and treated with medications insufficient
to control NMO disease activity such as
interferon-β or natalizumab. With increasing use of
AQP4-antibody tests, however, many patients with
first episodes or partial syndromes of ON, myelitis
or brainstem lesions have been reported with
AQP4-antibodies. In these patients, a positive
AQP4-antibody defines an NMO/NMO spectrum
disorders (NMOSD) diagnosis, leading to pro-
longed immunotherapies with most likely reduced
relapse rates. However, AQP4-antibody positivity
differs widely between studies (33–90%), suggest-
ing either poor sensitivities of some tests or false
positives in patients with clinically definite
NMO.17 18 False positives, which could lead to a
diagnosis of NMO in patients with less requirement
for aggressive/maintenance immunotherapies, have
potential management implications.
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Traditionally well-established and clinically defined patient
groups are used to calculate sensitivities, but this is difficult
when there are ‘seronegative’ patients, or patients who present
with partial or atypical features. In this multicentre study, we
compare AQP4 assay metrics on a mixed cohort of patient and
control sera performed by 15 European centres that routinely
test for AQP4-antibodies. We present a systematic approach that
identifies assays that are most useful clinically. This process and
results have implications for other antibody-mediated neuro-
logical disorders in this expanding area of clinical neurology.
METHODS
Ethics
The research use of referred sera was approved by the
Oxfordshire Research Ethics Committee ref 10/H0606/56, by
the ethical review board of the University of Heidelberg,
Germany, by the Regional and National Ethical Committee of
Hungary (3893.316-12464/KK4/2010 and 42341-2/2013/EKU,
Hungary), by the Ethics Committee of the Region of Southern
Denmark (ref S-20120066), by the French data protection
authority, by the regional committee for medical and health
research ethics, Western Norway (REK#3.2006.1235), follow-
ing Institutional Review Board (IRB) approval in Berlin,
Dusseldorf and Munich, Germany, and according to the Dutch
regulation for use of patient material.
Patient samples
All centres were asked to provide sera or plasma samples from 8
to 10 patients with AQP4-antibody positive or negative NMO
or NMOSDs, excluding cases with unclear diagnoses or diagno-
ses complicated by related pathologies, and a similar number of
clearly defined neurological control samples (eg, MS, other
inflammatory neurological disease). Four groups provided
samples only, whereas 15 groups performed assays only, and 6
groups provided samples and performed assays. A total of 209
coded sera/plasma samples were received by Euroimmun AG,
Germany from 10 centres by May 2013 (16 were excluded due to
insufficient volume, figure 1, table 1). The controls comprised
samples from patients with a headache (39), MS (35 relapsing
remitting, 2 primary progressive19), clinically isolated syndromes
(4, all exhibited clinical and paraclinical features typical of MS),
tumour (1 B-cell lymphoma, 1 colon carcinoma with neurological
complications), Susac syndrome (1), progressive encephalomyeli-
tis with rigidity and myoclonus (1), neuromyotonia (1), connect-
ive tissue disorder (1), myasthenia gravis (MG) (5) and acute
disseminated encephalomyelitis (120). The test samples comprised
50 samples from patients who fulfilled the 2006 diagnostic cri-
teria for NMO16 excluding AQP4 serostatus (35 submitted as
seropositive from different centres based on their different AQP4
assays), and 51 samples were from patients with clinical features
of NMO who did not meet the criteria (9 ON, 31 TM, and
11 with ON and TM; 39 submitted as seropositive by the centres;
these were referred to as NMOSD in the context of this study).
The NMO/spectrum disorder (SD) cohort was predominantly
female (4.6:1) with a median age at sampling of 45 years and the
samples were taken at a median of 3 years (range 0–30 years)
from disease onset, mostly during remission (3·35:1).
Study set-up and design
The clinical and paraclinical patient data were sent to the
University of Lübeck, Germany (PT). The samples were stored
at −20°C before recoding (EDEN001—EDEN193) and
Figure 1 Study design. The coded
clinical and serological data from 209
patients were sent to the University of
Lübeck, Germany. The coded serum
(199) or plasma samples (10) were
sent to Euroimmun, Lübeck, Germany.
Sixteen samples were excluded due to
insufficient volume. In total, 193
samples were recoded, aliquoted (90–
100 μL) and sent on dry ice to 15
European Centres to run 21 AQP4
assays with a 17-week deadline. Each
centre entered its own data online to a
web-based server maintained at the
Institute of Quality Assurance, Lübeck,
Germany. All clinical data, assay
results and sample codes were sent to
Oxford, UK and Lyon, France for initial
analysis. A blinded overview was sent
to each centre before unblinding the
study in a meeting in Paris, France,
where all groups were represented.
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aliquoted into 90–100 μl samples. These were distributed on
dry ice to the 15 participating centres, all of whom routinely
test for AQP4-antibodies (see figure 1 for a flow diagram of the
study design). A total of 17 weeks were allowed to perform the
assay and results were entered online via a password-protected
web-based interface established by the Institute for Quality
Assurance, Lübeck, Germany (MP). If more than one method
was used by a centre, results obtained from the different
methods were entered separately. Centres could provide semi-
quantitative results only (negative, +, ++, +++ or ++++),
or quantitative results. The semiquantitative data were converted
to 0–4 to give a score for individual sera.
After completion of the assays, the clinical and paraclinical
data from the University of Lübeck, a table of results from the
Institute of Quality Assurance, a list of the original and newly
assigned sample codes from Euroimmun, and all assay protocols
were submitted to two evaluating groups (Oxford, UK and
Lyon, France; figure 1). The data were analysed and a partially
unblinded ‘overview’ figure (see online supplementary figure S1)
was sent to all participants. All groups were represented at a
meeting in Paris, France where this data set was fully unblinded.
Assays
A total of 21 AQP4 assays were carried out (table 2): three live
cell-based assays (CBA); 10 fixed commercial CBAs
(Euroimmun AG, Lübeck, Germany), three of which were run
in-house by the manufacturer (CBA-EI) and seven at other diag-
nostic centres (CBA-EO); four flow cytometry assays (FACS);
three tissue-based assays using indirect immunofluorescence (2;
TBA-IIF) or an optimised immunohistochemistry technique (1;
TBA-IHC); and one commercial ELISA (Iason, Graz, Austria).
All assay protocols (see online supplementary appendix I) and
Table 1 Origin of samples
Centre Setting NMO NMOSD Control
Odense,
Denmark
MS Clinic, Department of
Neurology, Odense University
Hospital
7 0 0
Lyon, France Department of Neurology A,
Lyon University Hospital
9 6 15
Munich,
Germany
MS Clinic, Klinikum rechts der
Isar der TU München, Klinik für
Neurologie,
6 2 8
Pécs, Hungary Clinical and Experimental
Neuroimmunology Division,
Department of Neurology,
University of Pécs
7 7 1
Rotterdam,
Netherlands
MS Clinic, MS Centre ErasMS,
Erasmus MC, Rotterdam
9 9 5
Oxford, UK NHS National Specialised
Services for Neuromyelitis Optica
5 17 14
Berlin,
Germany*
NeuroCure Clinical Research
Center (NCRC), Charité
Universitätsmedizin Berlin
2 2 4
Düsseldorf,
Germany*
Department of Neurology,
Medical Faculty, Heinrich–
Heine–University Düsseldorf
0 0 39
Heidelberg,
Germany*
Molecular Neuroimmunology
Group, Department of
Neurology, University of
Heidelberg, Germany
6 6 4
Bergen,
Norway*
Department of Neurology,
Haukeland University Hospital
0 1 2
Total 51 50 92
Coded serum or plasma samples were submitted from 10 centres.
*Four centres submitted samples only and did not perform assays.
NMO, neuromyelitis optica; NMOSD, NMO spectrum disorder.
Table 2 Assays
Assay number Assay Isoform Transfection [Serum] Detection Quantitative
1 Live CBA M23 Transient 1:20 Fluorescence Semi
2 Live CBA M23 Transient 1:20 Fluorescence Semi
3 Live CBA M23 Transient 1:20 Fluorescence Semi
4 Fixed CBA EI M23 Transient 1:10 Fluorescence Semi
5 Fixed CBA EI M1 Transient 1:10 Fluorescence Semi
6 Fixed CBA EI M1 Transient 1:10 Fluorescence Semi
7 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
8 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
9 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
10 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
11 Fixed CBA EO M1 Transient 1:60 Fluorescence Semi
12 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
13 Fixed CBA EO M1 Transient 1:10 Fluorescence Semi
14 FACS M23 Transient 1:20 Fluorescence Yes
15 FACS M23 Stable 1:100 Fluorescence Yes
16 FACS M23 Transient 1:50 Fluorescence Yes
17 FACS M1 Stable 1:100 Fluorescence Yes
18 TBA-IHC-rat NA NA 1:200 Colorimetric Semi
19 TBA-IIF-rat/monkey NA NA 1:10 Fluorescence Semi
20 TBA-IIF-mouse NA NA 1:60 Fluorescence Semi
21 ELISA M23 NA 2:3 Colorimetric Yes
The basic characteristics of each assay are presented in six columns.
FACS, flow cytometry; Fixed CBA EI, fixed cell-based assay done in-house at Euroimmun AG; Fixed CBA EO, fixed cell-based assay (Euroimmun AG commercial assay) run at different
European diagnostic centres; Live CBA, live cell-based assay; NA, not applicable; TBA-IHC, indirect immunohistochemistry on tissue sections; TBA-IIF, indirect immunofluorescence on
tissue sections.
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data from each test are provided (see online supplementary
appendix II).
Statistics
The sensitivity, specificity, positive and negative likelihood
ratios, and their 95% CIs were calculated using MedCalc
V.15.8. Assay accuracy was calculated as (((true positives (TP)
+true negatives (TN))/total samples)×100)). Intraclass correl-
ation (ICC) of the semiquantitative score for all assays was
used as a measure of agreement across the 21 assays using the
Real Statistics Resource Pack software (Release 4.3; www.
real-statistics.com) in patients with clinically definite NMO,16
excluding the minor criteria of AQP4-antibody seropositivity
and on the whole cohort.
RESULTS
Identification of specific assays using controls
Ninety-two coded control samples (37 MS, 39 headache and 16
other inflammatory disease) were sent randomly interspersed
with the test samples. Overall, 16 of the 21 assays were >95%
negative in the controls. Figure 2 displays the negative (white
cells) and positive results (graded pink (low positive) to red cells
(high positive)). Twelve assays were highly specific (0–1 false-
positive test results; grouped on the left-hand side of figure 2)
Figure 2 Assay specificity based on
results from the 92 randomised control
patient samples. These comprised 37
multiple sclerosis (35 relapsing
remitting, 2 primary progressive),
1 connective tissue disease,
1 neuromyotonia, 1 progressive
encephalomyelitis with rigidity and
myoclonus, 4 clinically isolated
syndrome, 1 acute disseminated
encephalomyelitis, 1 Susac syndrome,
2 tumour (1 B-cell lymphoma, 1 colon
carcinoma), 5 myasthenia gravis and
39 headache. Each column represents
an individual assay (see table 2 for
assay details) except for the first
column which shows the serostatus
assigned by the participating centre.
Assays are grouped on the basis of
their specificity in this cohort: assays
on the left-hand side have 0 or 1
false-positive results (12 assays),
whereas assays on the right-hand side
have more than 1 false-positive result
(9 assays). The assays are numbered
1–21: 1–3 are live cell-based assays
(CBAs), whereas 4–6 are fixed CBA
performed in-house at Euroimmun,
7–13 are fixed CBA performed at other
European centres, 14–17 are flow
cytometry assays, 18–20 are
immunohistochemistry assays with
detection based on enzymatic colour
change (18) or fluorescence (19–20),
and 21 is a commercially available
ELISA (Iason). Each row represents a
single serum sample. Positive results
are coloured pink to red with a
semiquantitative score from ‘1’ to ‘4’
inserted, whereas a negative result is
white.
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and included all three commercial CBAs performed in-house
(CBA-EI, n=3), five of seven performed at different centres
(CBA-EO, n=5), two of the three live CBAs, one of the four
FACS assays and one of the three TBA. However, another nine
assays produced from two to 10 positive results in this negative
control cohort, with two assays (12 and 17) finding 9 and 10
positives. However, there was very little consistency in the
results for any one serum between assays, supporting the ‘false
positivity’ of the results, except for one sample from a patient
with MG who was positive on six tests.
Defining AQP4-antibody-positive NMO
On the basis of the control data, any sample from patients with
clinical NMO, ON or TM who were positive on two or more of
these highly specific assays was considered seropositive NMO/
SD. Results from the 50 patients whose clinical features fulfilled
criteria for NMO independent of AQP4-antibody positivity are
presented in figure 3. At least six of the highly specific assays (on
the left-hand side of figure 3) identified 32/50 NMO sera (64%)
as positive (all submitted as seropositive) and these were classified
as AQP4-antibody-positive NMO, with the remaining 18 as
AQP4-antibody seronegative NMO. All samples submitted
as seronegative were negative on these specific assays. However,
among the 18 seronegative samples, 10 were positive on at
least one of the assays with lower specificity (right-hand side of
figure 3), including one serum submitted as positive. Using the
semiquantitative data provided by each centre (scoring samples
from 0 (negative) to 4 (highly positive)), there was substantial
concordance across all 21 assays for patients with clinically defin-
ite NMO (ICC of 0.753 (95% CI 0.669 to 0.831), with the com-
plete data set giving an ICC of 0.820 (0.785 to 0.851).
Defining AQP4-antibody-positive NMOSD
Very similar results were found in the 51 samples from patients
with NMOSD (9 ON, 31 TM and 11 with ON and TM) who
did not fulfil the criteria for NMO independent of antibody
status. Thirty-one samples (61%) were positive on at least 4/12
assays that were highly specific (figure 4). However, there were
six further sera that were identified as positive in only one or
two specific assays and variably in the less-specific assays. Three
were defined as AQP4-antibody positive as they were positive
on two assays and the results were 100% concordant using a
single technique (live CBA), while the remaining three samples
that were positive on a single assay were considered negative.
The NMOSD samples included nine from patients with NMO
who required AQP4-antibody seropositivity to fulfil the 2006
Wingerchuk criteria, of which seven were positive in 18–21 of
the 21 assays, and the other two were negative on all assays.
Overall, the average antibody binding scores did not differ
between the patients with NMO and NMOSD (figure 5A).
Overall AQP4 assay metrics
Assay sensitivity was based on the 66 samples defined as sero-
positive (32 NMO, 34 NMOSD) and the specificity based on
the 92 control samples and the 35 NMO (n=18) and NMOSD
(n=17) samples defined as seronegative (table 3). The specifici-
ties, sensitivities and accuracy (((TP+TN)/total tests)×100) for
the different types of assays are shown in figure 5B–D. Three
assays were 100% sensitive: 2/3 live CBAs, and 1/4 FACS; all
three were based on the transient expression of the human
AQP4-M23 isoform. A further 10 assays were over 92% sensi-
tive: the third live CBA (98.5%), a FACS assay (97.0%), a TBA
that used optimised immunohistochemistry rather than
immunofluorescence (TBA-IHC; 98.5%), and seven fixed CBAs
(92.4–93.9%) and demonstrated excellent concordance. The
remaining assays were between 51.5% and 86.4% sensitive
including three fixed CBAs (80.3–86·4%), two FACS assay
(69.7%, 83.3%), two TBA-IIF (51.5%, 84.8%) and the ELISA
(83.3%); 4/6 of these assays that employ recombinant antigen
used the AQP4-M1 isoform.
Figure 3 Defining the serostatus of
patients with neuromyelitis optica
(NMO). Results in patients with NMO,
defined by the 2006 Wingerchuk
criteria excluding AQP4 serostatus.
Results are presented as in figure 2,
with each column representing an
individual assay, apart from the first
column that shows the serostatus
submitted with the sample, and each
row represents an individual serum. A
positive result is graded in colour from
pink to red with a semiquantitative
score from ‘1’ to ‘4’ inserted. A
negative result is displayed as a white
box. Two individual results from
patients with seropositive NMO were
considered unevaluable by the testing
centre and were scored negative. In
total, 32 of 50 NMO samples are
considered seropositive as they were
positive on at least two of the specific
assays. The remaining 18 samples
were defined as seronegative NMO,
including one that was submitted as
seropositive. The numbers at the
bottom of the figure show the assay
sensitivity (%) based on these clinically
defined patients.
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Figure 4 A heatmap of the entire data set presented in a similar fashion to figures 2 and 3. Each column is an individual assay. They are in the
same order as in figures 2 and 3. Each row is an individual serum sample. Results are based on the semiquantitative scores; negative results are
blue and positive results range from yellow (low positive) to red (high positive). The control samples are shown in (A) and the neuromyelitis optica
(NMO) and NMO spectrum disorder (NMOSD) samples in (B). In total, 34 of 51 samples in the NMOSD are considered seropositive and 17
seronegative. The final serostatus of the NMO and NMOSD samples is listed on the right-hand side in B. The heatmap was generated using GENE-E
V.3.0.204 (http://www.broadinstitute.org/cancer/software/GENE-E/).
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Accuracy
If the sensitivity of the assays is based only on the results from
the total NMOSD cohorts, without taking into consideration
the results of the control samples, assays 12, 14 and 15 would
be considered more sensitive (68–72%) than assays 1, 2 and 4
(62–64%) by an average of 6% (figure 2). If we include the spe-
cificity data from the control cohort, the accuracy of these two
groups of assays is similar (77.8% vs 76.2%). However, this
study design does not take into account ‘false-positive’ results
within the correct clinical context found by assays 12, 14 and
15 (lower section of figure 2). The results from the seronegative
NMO/SD samples were combined with the control sera results
to measure assay specificity and assay accuracy was defined as
(((TP+TN)/total tests)×100). In this instance, a TP result
includes any positive result in the 66 patients with NMO/SD
defined as seropositive and a TN result is any negative result in
the control cohort or the seronegative NMO/SD patient samples
(figure 5D). The difference in accuracy between these two
groups is now clearer (99.3% vs 93.4%). Overall, the most
accurate assays are the CBAs either on live cells or on the fixed
CBA scored in-house by the company.
MG is a confounder for AQP4 assay studies
In this study, sera from five patients with MG without NMO/SD
were included as negative control samples. However, a propor-
tion of patients with MG go on to develop NMO. They can be
seropositive for AQP4 antibodies many years before they
develop clinical signs of NMO.21 Results in these patients are
difficult to classify when evaluating AQP4 assay performance
and should be omitted. To further illustrate this association, six
of the AQP4 seropositive patients from four different centres
had coexisting MG.
DISCUSSION
Over the past 10 years, a number of new antibody-mediated
CNS diseases have been discovered. The diseases are subacute
and need to be diagnosed promptly in order to establish
optimal treatments, but not all patients present with the full cri-
teria for the clinical syndrome and may require antibody positiv-
ity for diagnosis; conversely, some patients fulfil clinical criteria
but are persistently ‘seronegative’. Antibody assays, in sera or
CSFs, have been developed in many laboratories, but there are
no quality evaluation systems available yet, and both false-
negative and false-positive results can mislead the clinician.
Here, 15 European centres performed assays on the same ran-
domised coded sera from 101 patients with NMO or NMOSD
and 92 controls. Classification of the AQP4-antibody-positive
cohort was based on patients with the correct clinical phenotype
(NMO, ON, TM or ON+TM), and assays that were highly spe-
cific within the study. The selection process worked equally well
on patients with NMO or NMOSD. The results support the
high specificity and sensitivity of CBAs and of flow cytometry
and immunohistochemistry in individual centres, and demon-
strate the importance of multicentre studies to identify false-
positive results within clinically defined cohorts.
We used NMO as the model disease because patients with
NMO have a clinical phenotype that can be defined independ-
ent of antibody status and many laboratories are running the
AQP4 antibody assays. However, an important feature of these
assays is to identify accurately the patients with
AQP4-antibody-negative NMO since they relapse less and may
not require such aggressive immunotherapy.22–24 A study design
using clinically defined cohorts to determine assay sensitivity
does not identify the patients with AQP4-antibody-negative
NMO and false-positive results in this cohort would lead to
incorrect increases in assay sensitivity and specificity. This issue
cannot be detected in single assay studies, but is highlighted
when multiple assays are used on the same samples, and the
conclusions based on coherence between results.
The random inclusion of samples from neurological patients
who shared autoimmune or neurological features with
NMOSDs was therefore an essential first step to identify the
most specific assays. Having established the specificities with the
disease control data, we could then identify the patients within
the correct clinical context who were positive on at least two of
the most specific assays and define them as seropositive. We
were then able to define the patients with seronegative NMO,
and use the same approach to define the patients with
Figure 5 Overall metrics of the AQP4 assays. Sixty-six samples
were considered seropositive: 32 NMO and 34 NMOSD. Using the
semiquantitative scores of 0–4 for each assay result, there was no
difference in the average assay score across 21 assays between the
NMO and NMOSD groups (A). (B–D) The assays are grouped by assay
type on the x-axis with the study assay number in parentheses. The
sensitivity (B) of assays was based on the samples classified as
AQP4-antibody positive NMO or NMOSD (66 in total). The specificity
(C) is based on the 92 control samples and the 35 seronegative NMO/
SD samples. The accuracy (D) calculation was based on the categories
described above: (((true positive+true negative)/total tests)×100). CBA,
cell-based assay; IHC, immunohistochemistry; NMO, neuromyelitis
optica; NMOSD, NMO spectrum disorder; SD, spectrum disorder.
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Table 3 Assay metrics based on 66 AQP4 positive samples and 127 controls
Sensitivity Specificity LRs Accuracy
Assay
number
Seropositive
NMO (32)
Seropositive
NMOSD (34)
TP
total
(66) Sensitivity 95% CI
Cons
(92)
Seronegative
NMO (18)
Seronegative
NMOSD (17)
TN
total
(127) Specificity 95% CI
Positive
LR 95% CI
Negative
LR 95%CI
((TP+TN)/
193)×100
1 32 34 66 100.0 94.6 to 100 1 0 0 126 99.2 95.7 to 100 127 18.03 to 894.7 0 99.5
2 31 34 65 98.5 91.8 to 100 1 0 2 124 97.6 93.3 to 99.5 41.7 13.6 to 127.6 0.02 0.00 to 0.11 97.9
4 32 30 62 93.9 85.2 to 98.3 0 0 0 127 100.0 97.1 to 100 ∞ 0.06 0.02 to 0.16 97.9
5 31 30 61 92.4 83.2 to 97.5 0 0 0 127 100.0 97.1 to 100 ∞ 0.08 0.03 to 0.18 97.4
6 31 30 61 92.4 83.2 to 97.5 0 0 0 127 100.0 97.1 to 100 ∞ 0.08 0.03 to 0.18 97.4
8 31 30 61 92.4 83.2 to 97.5 0 0 0 127 100.0 97.1 to 100 ∞ 0.08 0.03 to 0.18 97.4
7 32 29 61 92.4 83.2 to 97.5 1 0 0 126 99.2 95.7 to 100 117.4 16.6 to 827.9 0.08 0.03 to 0.18 96.9
18 31 34 65 98.5 91.8 to 100 4 0 1 122 96.1 91.1 to 98.7 25 10.6 to 59.1 0.02 0.00 to 0.11 96.9
14 32 34 66 100.0 94.6 to 100 5 2 0 120 94.5 89.0 to 97.8 18.1 8.8 to 37.3 0 96.4
3 32 34 66 100.0 94.6 to 100 5 0 2 120 94.5 89.0 to 97.8 18.1 8.8 to 37.3 0 96.4
9 31 30 61 92.4 83.2 to 97.5 2 0 0 125 98.4 94.4 to 99.8 58.7 14.8 to 232.5 0.08 0.03 to 0.18 96.4
10 28 29 57 86.4 75.7 to 93.6 0 0 0 127 100.0 97.1 to 100 ∞ 0.14 0.07 to 0.25 95.3
11 29 27 56 84.8 73.9 to 92.5 0 0 0 127 100.0 97.1 to 100 ∞ 0.15 0.09 to 0.27 94.8
19 27 29 56 84.8 73.9 to 92.5 0 0 0 127 100.0 97.1 to 100 ∞ 0.15 0.09 to 0.27 94.8
16 29 26 55 83.3 72.1 to 91.4 0 0 0 127 100.0 97.1 to 100 ∞ 0.17 0.1 to 0.29 94.3
15 32 32 64 97.0 89.5 to 99.6 5 2 4 116 91.3 85.0 to 95.6 11.2 6.4 to 19.7 0.03 0.01 to 0.13 93.3
13 27 26 53 80.3 68.7 to 89.1 0 0 1 126 99.2 95.7 to 99.98 102 14.4 to 721.1 0.2 0.12 to 0.32 92.7
21 28 27 55 83.3 72.1 to 91.4 3 0 1 123 96.9 92.1 to 99.1 26.5 10.0 to 69.8 0.17 0.1 to 0.3 92.2
12 31 31 62 93.9 85.2 to 98.3 9 4 5 109 85.8 78.5 to 91.4 6.6 4.3 to 10.2 0.07 0.03 to 0.18 88.6
17 24 22 46 69.7 57.2 to 80.4 9 2 1 115 90.6 84.1 to 95.0 7.4 4.2 to 12.9 0.33 0.23 to 0.48 83.4
20 17 17 34 51.5 38.9 to 64.0 2 2 0 123 96.9 92.1 to 99.1 16.4 6.1 to 44.1 0.5 0.39 to 0.64 81.3
The assays are ordered on the basis of accuracy, which is calculated as (((TP+TN)/total tests)×100). The sensitivity, specificity, positive and negative LRs, and their 95% CIs from 21 individual assays to detect AQP4-antibodies from 15 European diagnostic
centres are presented along with assay accuracy.
Assays 5 and 6 use similar AQP4-M1 transfected cells that form part of two different biochip mosaics.
Cons, controls; LR, likelihood ratio; NMO, neuromyelitis optica; NMOSD, NMO spectrum disorder; TN, true negative; TP, true positive.
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seropositive NMOSD, where there is the most clinical uncer-
tainty. Addition of the patients with defined seronegative NMO
and NMOSD to the control cohort improved the outcome
measure of these assays for clinical use.
This post-study analysis also suggests a benefit of using the
M23 isoform of AQP4 for optimal sensitivity with the top three
ranked assays based on the transient expression of the human
AQP4-M23 isoform. The live CBAs employ AQP4-M23 trans-
fected cells and consistently perform well25 26 but are technically
demanding and time-consuming, limiting their use except in spe-
cialist centres. Additionally, we do not have data from an
AQP4-M1 live CBA within the study for direct comparison. The
commercially available CBA is likely to become the standard for
centres throughout the world; overall, it performed well
in-house and in most other centres but issues at one or two
centres need resolution. Perhaps surprisingly, the flow cytometry
assays produced the greatest variations in sensitivity (69.7–
100%) and specificity (90.6–100%); however, these can be
explained by differences in assay methodology, sample process-
ing and cut-off determination. The differences in data from
centres using similar technologies suggest that experience with
individual techniques impacts on the data produced. The flow
method has the potential advantages of processing many samples
together, establishing cut-offs based on multiple control sera and
establishing independently any non-specificity of the sample (for
instance, non-specific binding to the untransfected cells) all in a
quantitative manner; hence, it should be pursued further. The
immunohistochemistry on fixed tissue sections, originally used
to define AQP4-IgG but considered poorly sensitive,26 was
highly sensitive in one centre27 and could be used as an initial
screening test with confirmation of positives by an antigen-
specific CBA in centres where the costs of performing all assay
requests on expensive commercial tests would be prohibitive.
This study design improves the assessment of AQP4 assays
and provides a method to compare similar assays based on other
targets. However, further study design improvements could be
made. More control samples, particularly autoimmune samples,
should be included but ambiguous patient cohorts, as is the case
with patients with MG when studying AQP4 antibodies, should
be considered separately. In one or two centres, individual
assays (immunohistochemistry and flow cytometry) were excel-
lent. In future studies, all assays to be tested should be imple-
mented at multiple sites to evaluate assay reliability and
reproducibility. In addition, multiple testing at a single centre
may be helpful in adding confidence to test results in a routine
clinical setting, but it could impact on interpretation of subject-
ive results of the individual tests. Moreover, since all samples
were sent in a single shipment, the assays had not necessarily
been performed under conditions which would apply to the
testing of samples that might be referred routinely. Continued
assessment of a low number of samples sent intermittently to
these laboratories through routine channels, as in external
quality assurance services (EQAS), would be essential to
monitor testing at all centres in the future.
The importance of antibody diagnostics is undoubted, with a
large number of different antibodies now identified in a wide
range of neurological diseases involving different forms of
encephalitis or demyelinating/white matter conditions. For
instance, identification of AQP4-antibodies is important to
confirm a clinical diagnosis of NMO and ensure optimal treat-
ment, as well as to define accurately those patients with partial
phenotypes (NMOSDs) who are treated in a similar manner. In
addition, greater emphasis is now placed on assay outcome in
patient diagnosis according to the new NMOSD diagnostic
criteria.28 False-positive results, highlighted in this study, need
to be avoided because of the risk of overaggressive immunother-
apies in patients with alternative diagnoses. These aspects will
be even more important in diseases where there are no estab-
lished clinical criteria such as in patients with myelin oligo-
dendrocyte glycoprotein (MOG) antibodies who can present
with a phenotype similar to NMO but are less likely to suffer
long-term disability,29 or anti-NMDA receptor encephalitis
where the diagnosis partly depends on detection of the anti-
body.30 This study demonstrates the feasibility and advantages
of performing multicentre comparisons of specificities and sensi-
tivities and identifying and solving specific difficulties in the
tests. The outcomes should improve the accuracy and confi-
dence in AQP4-antibody testing, and suggest a way to carry out
these studies in diseases where the clinical associations are less
well established.
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